

CELL CULTURE & BIOPROCESSING

11 - 12 November 2025 | London, UK

Day 1 Track 1 – Cell Line Engineering Ensuring Stability, Quality & Clonality

- Improving efficiency and removing bottlenecks in cell line development
- Clone selection strategies and establishing monoclonality
- Screening clones for productivity and titer
- Strategies for single-cell isolation
- Predicting & characterizing clones
- Improving the stability of cell lines via optimized transfection
- Gene delivery & editing for cell line development
- Regulatory considerations to develop stable cell lines
- Novel formats

Day 1 Track 2 – Upstream Bioprocessing

- High throughput technologies in bioprocessing
 - Automation & robotics
 - o Software & Al
- Improving instrumentation for biopharmaceutical drug production
- Bioreactors & perfusion systems
- Leveraging ADC's to streamline drug production processes
- High containment solutions for ADCs
- Online monitoring techniques
- Online sensors for cell culture
- Scale up
- Manufacturing biopharmaceuticals with microbial systems
- Challenges in replacing human components
- Process characterisation approaches
- Changing molecule formats

Day 2 Track 1 – Generation & Validation of Pre-Clinical Models: Cell Culture Media & 3D Cultures

- Advances in 3D cultures and their role in translational research
- Integration of iPSC models for pre-clinical studies
- Strategies to progress research with or without animal models
- Case studies highlighting successes and failures
- Real-world examples of assay development and validation
- Insights into gene target validation and optimization
- Optimising cell culture & media development:
 - o Techniques for enhancing cell culture productivity
 - Media development, analysis, and regulatory considerations
- Lessons from cellular agriculture and supply chain challenges
- Integration of cryopreservation techniques and toxicology evaluations in pre-clinical assays

Day 2 Track 2 – Downstream Bioprocessing

- Data for downstream processing
- PAT tools for predictivity
- Facilitating technology transfer for cell-based products
- Reducing timelines in bioprocessing
- Host cell proteins & removing impurities
- Analytical approaches AV characterisation, process monitoring & product analysis
- How to deal with large protein quantities generated by upstream bioprocessing
- Viral validation new considerations & approaches
- Establishment of fast microbiological testing



Benefits to Attending

- ✓ Hear from and meet with the key innovators in cell culture & bioprocessing. 2024 attendees included: Chief Scientific Officer, Medigene AG; Senior Vice President, Global Regulatory Affairs, BioNTech SE
- New to 2025! Gain invaluable insights into innovations in pre-clinical assay development & 3D cell cultures. Key opinion leaders will be addressing the integration of iPSC models for pre-clinical studies, 2D versus 3D cultures and case studies highlighting pre-clinical successes and failures
- New to 2025! Take a deep dive into the latest strategies for enabling successful cell line engineering – improving efficiency and removing bottlenecks in cell line development, screening clones for productivity, predicting & characterising
- Devised with the help of our esteemed advisory board. Key presentations will cover gene delivery in drug discovery, automation & digitalisation in bioprocessing and techniques for enhancing cell culture productivity
- Join thought-leader panel discussions, investor-focused sessions and roundtables pertaining to the latest in cell culture & bioprocessing

2025 Speakers Include:







Rhiannon David AstraZeneca

Vincenzo Di Cerbo Cell & Gene Therapy Catapult

Anna Nowocin MHRA

Meet Senior Decision Makers

1000+ attendees at Cell 2025 from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Cell Line Engineering	
Cell Culture	
Upstream Processing	

Downstream Processing Cell Line Development Quality Control

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Bioprocessing Solutions Instruments & Consumables Cell Line Development

Cell Culture Media Genomic Technologies Automation



ADVANCED THERAPY DEVELOPMENT

11 - 12 November 2025 | London, UK

Day 1 Track 3 - Gene Therapy Discovery & Development

- Vector engineering: designing and optimizing viral and non-viral vectors for efficient therapeutic delivery
- Next-gen strategies: gene editing technologies
- Preclinical validation, assessing safety and efficacy, including offtarget effects
- How do we design a gene therapy clinical trial?
- Nonmonogenetic gene therapies

Day 1 Track 4 – Cell & Gene Therapy Analytics & Quality Control

Part 1 – Cell Therapy Analytics

- Raw material management
- Analysing and monitoring processes to ensure product quality
- Starting materials, process control
- Characterising cell-based therapies
- Incorporation of omics, AI/ML to close the gaps in data
- Novel approaches to cell culture process control strategies
- Quality control
- Formulation development with AI/ML
- Healthy donor considerations

Part 2 - Gene Therapy Analytics

- Vector characterisation
- Gene expression analytics
- Formulation development with AI/ML & overcoming stability & characterisation challenges
- Assay development potency assays & validation of assays

New to 2025! Day 1 Track 5 - Tissue Engineering Development

- Tissue engineering development •
- Stem cells for cartilage
- Stem cells for diabetes (e.g. Vertex is leading in this space)
- Biomaterials for tissue engineering
- Tissue engineering with different cell types: MSCs, iPSCs, fibroblasts, NPCs

Benefits to Attending

- New to 2025! Take a deep dive into regulatory considerations for cell & gene therapies. Key opinion leaders will be covering the regulations surrounding the development of platforms for genetically modified B cells and using accelerated regulatory pathways
- New to 2025! Gain invaluable insights into tissue engineering development, with presentations addressing stem cells for cartilage, biomaterials for tissue engineering and tissue engineering with different cell types

Meet Senior Decision Makers

1000+ attendees at Cell 2025 from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Cell Therapy Gene Therapy Stem Cells

CAR-T Development **Clinical Development** Market & Patient Access

Regulatory Innate Killer Cells Vector Expression

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Off-The-Shelf Therapies Safety Profiling Viral Vectors

Characterisation CRISPR / Gene Editing Stem Cell Development

Off-The-Shelf Therapies Safety Profiling Viral Vectors

Characterisation CRISPR / Gene Editing Stem Cell Development



Day 2 Track 3 – Cell Therapy Discovery & Development

- NK, TCR, innate killer cell therapies
- Combination therapies for immunotherapeutic response
- Cell therapies for solid tumors, blood-based cancers & autoimmune diseases
- Part 2 iPSCs and Stem Cell Therapy Development
- Delivering stem cell therapies from discovery to the clinic Stem cell discovery & development: neurodegenerative & cardiovascular diseases, paediatrics
- The role of stem cell-derived disease models in drug discovery •
- Bioprinting & biomaterials within stem cell therapy
- The use of stem cells in regenerative medicine & tissue engineering
- Derivation, manipulation, and characterization of iPSCs
- Strategies to control and optimise stem cell bioprocessing

Day 2 Track 4 - Clinical Development & Clinical Trials for Cell & **Gene Therapies**

- Defining a clinical trial strategy for CGT therapies
- From bench to bedside-translational case studies
- Improving CAR-T potency for solid tumours
- Patient engagement in clinical trials and patient-centered clinical trial design
- Real-world evidence and post market surveillance
- CRISPR use within clinical trials
- Individualised therapy considerations in clinical trials
- The roadmap for the first human clinical trial
- Data integrity

New to 2025! Day 2 Track 5 - Regulatory Considerations for Cell & **Gene Therapies**

Part 1 – Cell Therapies

- Data integrity
- CAR-T therapies
- Regulations surrounding the development of platforms for genetically modified B cells
- Ex vivo & systemic lentiviral stem cell therapies •
- Considerations for rare disease & innovative clinical trial designs
- Clinical translation of cell-based products

Part 2 – Gene Therapies

- Using accelerated regulatory pathways
- Applications of biomarkers for accelerated regulatory pathways
- Ex vivo gene therapy approaches
- Strategies for rare diseases
- Post-market surveillance, safety, efficacy, patient outcomes

Clinical Trails Tissue Engineering Tissue Development



CELL & GENE THERAPY MANUFACTURING

11 - 12 November 2025 | London, UK

Day 1 Track 6 - Strategies & Challenges for Gene Therapy Manufacturing

- Scale-up challenges and strategies
- Implementing continuous manufacturing processes
- Quality by Design approaches
- Utilizing single-use technologies
- Leveraging bioinformatics and digital twin technology
- Scalable platforms for vector production; optimising quality and yield
- Transitioning from R&D to clinical manufacturing: navigating the path to commercialisation
- Lipid nanoparticles & biodistribution
- Sustainable manufacturing, cost effectiveness & scalability integration

Day 1 Track 7 – Supply Chain, Logistics & Commercialisation

- Regulatory compliance in transportation and storage
- Cold chain management for product integrity
- Optimizing transportation routes and inventory management
- Collaboration and partnerships across the supply chain
- Cryopreservation
- How to bring new modalities into the clinics shipping & tracking
- Strategies for commercialisation of CGT Therapies
- Regulatory & IP considerations
- Navigating competitive market landscapes
- Global market expansion
- Patient-centred product launch
- Off-the-shelf CGT therapies
- **Reimbursement strategies**
- Sustainable supply chain approaches

Day 2 Track 6 - Strategies for Cell Therapy Manufacturing

- Autologous vs. allogenic products
- Transitioning to cGMP manufacturing
- Regulatory insights and compliance considerations
- Ensuring sustainable product pipeline
- Analytical techniques: quality control and assurance
- Transitioning from R&D to clinical manufacturing: navigating the path to commercialisation
- Platform concepts how CAR-Ts can be manufactured & streamlining the pipelines
- Sustainable manufacturing

New to 2025! Day 2 Track 7 - Automation, AI & Robotics in Cell & **Gene Therapies Manufacturing**

- Automated cell therapy manufacturing
- Robotics in automating cell & gene therapy production
- Implementing smart manufacturing practices in cell therapy
 - production
 - Predictive assays 0
 - QC analytics for potency 0
- Media
 - Automation and digitisation in cell therapy manufacturing to enhance efficiency and quality: ML and data analytics
- Automated building systems
- Digitalisation approaches, methods & strategies
- Autologous manufacturing



Benefits to Attending

Hear from and meet with the key innovators in cell & gene therapy manufacturing. 2024 attendees included: Director Product Supply Cell & Gene, BioNTech SE; Vice President, Clinical Strategy and Development, Medigene; Chief Scientific Officer, CellProthera

Take a deep dive into strategies for gene therapy manufacturing. Key opinion leaders will cover the challenges associated with scale-up, utilising single-use technologies and sustainable manufacturing practices

- Benefit from the latest development in supply chain & logistics. Presentations will address regulatory compliance in transportation, shipping & tracking of new modalities in the clinic & collaborations across the supply chain
 - Explore strategies for cell therapy manufacturing with topic areas such as autologous vs allogenic products, automation & digitalisation, transitioning from R&D to clinical manufacturing & the path towards commercialisation
- New to 2025! Do not miss out on attending our vibrant Start Up Zone pitches on Day 1. Presentations will look at cell & gene therapy platforms, development and production, manufacturing & many more
 - New to 2025! Hear about emerging biotechs and spin offs working within CGT therapeutics development. The 'Innovation & Collaboration' programme running on Day 2 will look at areas such as regenerative medicine, commercialisation & cell- and gene-based therapeutics

2025 Speakers Include:







Ben Weil

Royal Free London NHS

Foundation Trust

Jose Bonafont

Maria Luisa Giorello Pfizer

Meet Senior Decision Makers

1000+ attendees at Cell 2025 from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Cell Therapy Gene Therapy Single-Use Technologies

Process Development **Cell Therapy** Manufacturing

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Process Improvement Automation Viral Vector Production Supply Chain Cold Chain **Raw Materials**

DanausGT

2025 Speakers:

Pharma & Biotech:

- Joanna Brewer, Chief Scientific Officer, Adaptimmune
- François Gianelli, Chief Regulatory & Quality Officer, TreeFrog Therapeutics
- Panteli Theocharous, Chief Therapeutics Officer & Head Of Medical & Scientific Affairs, Garuda Therapeutics
- Amit Rakhit, Chief Medical Officer, BlueRock Therapeutics
- Roelof Rongen, Chief Executive Officer, Adolore BioTherapeutics
- Debesh Mandal, Co-Founder & Chief Executive Officer, Nanograb
- Terri Gaskell, Chief Technology Officer, Rinri Therapeutics
- Peter Andersen, Chief Research & Development Officer, TreeFrog Therapeutics
- Nitin Patel, Vice President Of Late-Stage Clinical Development, Legend Biotech
- Thorsten Gorba, Vice President Process & Analytical Development, Aspen Neuroscience
- Maria Luisa Giorello, Global Gene Therapy Marketing Director, Pfizer
- Nicole Lund, Senior Quality Control Director, Bluerock Therapeutics
- Kerry Sieger, Senior Director, Global Quality Operations, Immatics
- Christopher Middendorf, Senior Director, Hogan Lovells
- Sarah Snykers, Senior Director of Operations, Legend Biotech
- Panos Kefalas, Director of Access Strategy, Cell & Gene Therapy Catapult
- Ben Weil, Director For Manufacturing, Royal Free London NHS Foundation Trust
 Rhiannon David, Director, Advanced Cell Models / Microphysiological Systems, AstraZeneca
- Chien-Chung Chen, Director of Analytical Development, Cabaletta Bio
- Rachana Mishra, Director Of Cell Biology & Co-Founder, Secretome Therapeutics
- Thijs Gerritzen, Director CMC Development, Amarna Therapeutics
- (Reserved) Rohan Sivapalan, Associate Director, Biologics & Cell Line Engineering, AstraZeneca
- Lydia Caro, Associate Director, Head Of Cell Sciences, Ichnos Sciences
- Evangelia Kokalaki, Associate Director of Immunobiology, Autolus
- (Reserved) Claire Kerridge, Head Of Gene Therapy, MHRA
- (Reserved) Sarah Kempster, Head Of Serological Standards, SR&I Diagnostics, MHRA
- Daria Marsh, Head of Bioprocessing, Cell and Gene Therapy Catapult
- Yaser Alkhatib, Head of Laboratory, Boehringer Ingelheim
- Himansu Patel, Head of Quality Innovation, Cell and Gene Therapy Catapult
- (Reserved) Catarina Brito, Principal Investigator & Head Of Advanced Cell Models Lab, iBET
- Parag Kumthekar, Gene Therapy Downstream Process Development Lead, UCB
- Sarah McAleer, Pharmacy Lead Innovative Treatments, NHS
- Monique Schloetter, Scientific Expert Cell Therapies Upstream Development, Bayer
- Bart Royens, Senior Process Engineer, Manufacturing Sciences, Sanofi
- Sally Gu, Senior Associate, Hogan Lovells
- Jose Bonafont, Principal Scientist, DanausGT
- (Reserved) Suzanne Gibson, Principal Scientist Cell Line Development & Engineering, AstraZeneca
- (Reserved) Tatyana Ponomaryov, Principal Scientist, Plasticell
- Julie Beaudet, Chemistry, Manufacturing, & Control Senior Staff Scientist, Regeneron
- Vincenzo Di Cerbo, Lead Scientist, Cell and Gene Therapy Catapult
- Felix Roth, Senior Scientist, AstraZeneca
- Niraimathi Govindasamy, Senior Scientist, Bluu Bio
- James Matthews, Senior Scientist, PureSpring Therapeutics
- (Reserved) Patrikas Pultinevicius, Senior Scientist, Cell Line Development & Automation, AstraZeneca

Academic Representatives:

- Tiffany Rao, Professor Biochemistry & Cell Biology, University College Cork
- Aline Miller, Professor, University of Manchester

Innovation & Collaboration Track:

- Clare Selden, Professor of Experimental Hepatology, University College London
- Sanjeev Luther, President & Chief Executive Officer, Eterna Therapeutics
- (Reserved) Debesh Mandal, Co-Founder & Chief Executive Officer, Nanograb
- (Reserved) Evripidis Lanitis, Head of Process Development, Cellula Therapeutics
- (Reserved) Nozhat Choudry, Vice President Of Clinical Development, Nanoscope Therapeutics
- (Reserved) Sudhish Sharma, Co-Founder & Director Of Preclinical Studies, Secretome Therapeutics

New to 2025! Featuring Our Vibrant Start Up Zone

The Start Up Zone programme is designed to support young start-ups working on new technologies, platforms, solutions to showcase their innovative thinking and bring new ideas. Featuring on Day 1 of the event, participating companies receive full conference pass, 10-minute pitch and a 1x1m space in the start up zone, alongside their logo being featured on the website and event platform.

To apply, visit the website or email Faye Moffat at f.moffatt@oxfordglobal.com

Topics Will Cover:

Cell Culture & Bioprocessing, Cell Therapy Development, Gene Therapy Development, Cell Therapy Platforms, Gene Therapy Platforms, CGT Production & Manufacturing

New to 2025! Innovation & Collaboration Programme

Running on Day 2 of the event, this programme features 10-minute presentations from emerging biotechs and academic spin-offs advancing cell culture development, advanced therapies and manufacturing, with specific focus on IP, funding priorities & challenges, cell & gene therapy investments. Designed to boost visibility, attract collaborators & partners, it connects innovators with pharma leaders, investors, solution providers, and large biotechs. Don't miss these presentations for cutting-edge ideas and collaboration & partnership opportunities.

Topics Will Cover:

Investor Perspectives of Cell & Gene Therapies, IP Strategies, Commercialisation Approaches for Cell & Gene Therapies, Manufacturing, Production & Supply Chain, Cell Culture & Cell Culture Models

2025 Cell Sponsors:

Platinum Sponsor:



Kick Off Day 10th November 2025

13.00 - 13.30	Registration		
	Cell Culture & Bioprocessing	Advanced Therapy Development	Cell & Gene Therapy Manufacturing
	Novel Tools For Cell Line Development	Gene Therapy Development	Autologous vs. Allogenic Products
13.30 - 13.55	Industry Presentation: Unravelling HEK293 Cell Biology To Improve Manufacturing Bottleneck RESERVED: Suzanne Gibson, Principal Scientist – Cell Line Development & Engineering, AstraZeneca	Industry Presentation: Vector Engineering	Industry Presentation: Case Study For Autologous Products
13.55 - 14.20	Industry Presentation: Novel Formats	Industry Presentation: Next-Gen Strategies: Gene Editing Technologies	Industry Presentation: Case Study For Allogenic Products
14.20 - 14.45	Roundtable Discussion 1: Emerging Technologies For High-Throughput Cell Line Screening And Selection Roundtable Discussion 2: Leveraging Automation And AI For Optimising Growth, Productivity, And Stability	Roundtable Discussion 1: Optimising Vector Design For Next-Gen Gene Therapies Roundtable Discussion 2: Gene Therapy Delivery Beyond The Liver	Roundtable Discussion 1: Scaling Up For Success: Navigating Gene Therapy Manufacturing Roundtable Discussion 2: Automation In CGT Manufacturing
14.45 - 15.00	Refreshments		v
15.00 - 17.00	Sponsored Workshop	Sponsored Workshop	Sponsored Workshop
	BIOSYSTEMS	For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	SVIPCTSAS
17.00	End of Day	·	

07.30	Registration										
08.45 - 08.55	Oxford Global's Welcome Address										
08.55 - 09.00	Event Moderator's Welcome										
09.00 - 09.45	Opening Keynote Address & Q&A Session: Accelerating Al-Driven R&D For Cell & Gene Therapies										
	Cell Culture & Bioprocessing Advanced Therapy Development Cell & Gene Therapy Manufacturing										
09.45 - 10.10	Programme Keynote Address: Improving Pre-Clinical Safety Assessment With Advanced Cell Models CONFIRMED: Rhiannon David, Director, Advanced Cell Models / Microphysiological Systems, AstraZeneca	Programme Keynote Address: Preclinical CGT Assessments: Research & Development	Programme Keynote Address: Strategic Analytical & Quality Control Components For Cell & Gene Therapy CONFIRMED: Nicole Lund, Senior Quality Control Director, Bluerock Therapeutics	Programme Keynote Address: Global Site Qualification & Impact On Supply Chain Logistics							
10.10 – 10.35	Solution Provider Presentation	Platinum and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Platinum and Above Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Platinum and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com							
10.35 – 11.00	Industry Presentation: Cell Line Development	Industry Presentation: Evolution Of Advanced Therapy Regulations CONFIRMED: Sally Gu, Senior Associate, Hogan Lovells	Industry Presentation: Advances In Cell Therapy Development – Recent Approvals	Industry Presentation: Integrating Development, Manufacturing, & Regulatory Considerations Into ATMPs CONFIRMED: Tiffany Rau, Professor Biochemistry & Cell Biology, University College Cork							
11.00 - 12.00		Morning Bre Poster Pres 1-2-1	eak & Refreshments sentation Sessions Meetings x3								

	Cell Culture & Bioproce	essing	Advanced Therapy Dev	velopment		Cell & Gene Therapy M	anufacturing			
	Track 1 – Cell Line Engineering Ensuring Stability, Quality & Clonality	Track 2 – Upstream Bioprocessing	Track 3 – Gene Therapy Discovery & Development	Track 4 – Cell & Gene Therapy Analytics & Quality Control	Track 5 – Tissue Engineering Development	Track 6 – Strategies & Challenges For Gene Therapy Manufacturing	Track 7 – Supply Chain, Logistics & Commercialisation	Start Up Zone Programme		
12.00 - 12.25	Industry Presentation: Gene Delivery & Editing For Cell Line Development	Industry Presentation: Develop Processes For The Generation Of Novel Cellular Medicines	Industry Presentation: Pre-Clinical Validation: Gene Therapy For Chronic Pain	Industry Presentation: Assay Qualification & Validation	Industry Presentation: UK Stem Cell Bank	Industry Presentation: Gene Therapy Manufacturing Strategies	Industry Presentation: Hospital Readiness For Dosing From An Industry Perspective	Start Up Pitch x2 Start Up Pitch x2		
	RESERVED: Rohan Sivapalan, Associate Director, Biologics & Cell Line Engineering, AstraZeneca	CONFIRMED: Monique Schloetter, Scientific Expert Cell Therapies - Upstream Development, Bayer	CONFIRMED: Roelof Rongen, Chief Executive Officer, Adolore BioTherapeutics	CONFIRMED: Kerry Sieger, Senior Director, Global Quality Operations, Immatics	RESERVED: Claire Kerridge, Head Of Gene Therapy, MHRA	CONFIRMED: Thijs Gerritzen, Director CMC Development, Amarna Therapeutics	CONFIRMED: Maria Luisa Giorello, Global Gene Therapy Marketing Director, Pfizer			
12.25 - 12.50	Solution Provider	Solution Provider	Solution Provider	Solution Provider	Gold and Above	Gold and Above	Gold and Above	Attendees are welcome		
		BIOMÉRIEUX	GenScript	รงราวราง	Presentation For sponsorship opportunities please contact: <u>sponsorship@oxford</u> <u>global.com</u>	Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	presentations		
12.50 - 13.50	Lunch									
	Poster Presentations Sessions 1-2-1 Meetings x3									
				 Fireside Chats on the Theme 1 – Patient A 	'Visionary Voices Stage' dvocacy & Patient Engage	ment				

	Cell Culture & Bioproce	essing	Advanced Therapy Development			Cell & Gene Therapy Manufacturing		
	Track 1 – Cell Line Engineering Ensuring Stability, Quality & Clonality	Track 2 – Upstream Bioprocessing	Track 3 – Gene Therapy Discovery & Development	Track 4 – Cell & Gene Therapy Analytics & Quality Control	Track 5 – Tissue Engineering Development	Track 6 – Strategies & Challenges For Gene Therapy Manufacturing	Track 7 – Supply Chain, Logistics & Commercialisation	Start Up Zone Programme
13.50 - 14.15	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Silver or Above Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxford</u> <u>global.com</u>	Solution Provider Presentation	Silver or Above Solution Provider Presentation	Attendees are welcome to join the co-located presentations
14.15 - 14.40	Industry Presentation: Unravelling HEK293 Cell Biology To Improve Manufacturing Bottleneck CONFIRMED: Vincenzo Di Cerbo, Lead Scientist, Cell and Gene Therapy Catapult	Panel Discussion: Innovations & Challenges In Upstream Bioprocessing: Navigating The Future Of Cell Culture & Bioprocessing • Cell line development & optimization • Automation & process control	Industry Presentation: Site Specific Gene Therapy For Kidney Diseases CONFIRMED: James Matthews, Senior Scientist, PureSpring Therapeutics	Panel Discussion:Navigating TheAnalytical Lifecycle:StrategicManagement ForStreamlined CGTProductDevelopment• End-to-endanalytical strategy• Data-drive decisionmaking• Risk management& quality control	Industry Presentation: Creating Durable Blood Stem Cell Therapies CONFIRMED: Panteli Theocharous, Chief Therapeutics Officer & Head Of Medical & Scientific Affairs, Garuda Therapeutics	 Panel Discussion: Sustainability & Outsourcing In Gene Therapy Manufacturing Price considerations Facilitating sustainability Sustainability at clinical stage 	Industry Presentation: Unlock The Value Chain Of Your CGT Operations: Supply Chain Design To Support Commercial Operations	Start Up Pitch x2
14.40 - 15.05	Industry Presentation: Controlling Gene Expression In Mammalian Cell Lines	• Stability & process control	Industry Presentation: Proteo-Lipid Vehicles for Precision Gene Therapy		Industry Presentation: Organoid Development & Applications		Industry Presentation: Strategies For Commercialisation Of CGT Therapies	Start Up Pitch x2 Start Up Pitch x2
	RESERVED: Patrikas Pultinevicius, Senior Scientist, Cell Line Development & Automation, AstraZeneca	Panellists: Felix Roth, Senior Scientist, AstraZeneca	RESERVED: Jitendra Kumar, Lead Scientist, Entos Pharma	Panellist: Nicole Lund, Senior Quality Control Director, Bluerock Therapeutics		Panellist: Thijs Gerritzen, Director CMC Development, Amarna Therapeutics		

Cell 2025 Day 1 – 11th November 2025

	Cell Culture & Bioproce	essing	Advanced Therapy Development			Cell & Gene Therapy M					
	Track 1 – Cell Line Engineering Ensuring Stability, Quality & Clonality	Track 2 – Upstream Bioprocessing	Track 3 – Gene Therapy Discovery & Development	Track 4 – Cell & Gene Therapy Analytics & Quality Control	Track 5 - Tissue Engineering Development	Track 6 - Strategies & Challenges For Gene Therapy Manufacturing	Track 7 – Supply Chain, Logistics & Commercialisation	Start Up Zone Programme			
15.05 - 15.30	Solution Provider Presentation	Solution Provider Presentation	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglo</u> <u>bal.com</u>	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglo</u> <u>bal.com</u>	Solution Provider Presentation	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Attendees are welcome to join the co-located presentations			
15.30 - 16.30	0 Afternoon Break & Refreshments Poster Presentation Sessions 1-2-1 Meetings x3										
16.30 - 16.55	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Bronze Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglo bal.com	Solution Provider Presentation	Bronze Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl	Attendees are welcome to join the co-located presentations			

	Cell Culture & Biopro	ocessing	Advanced Therapy Development			Cell & Gene Therapy Manufacturing		
	Track 1 – Cell Line Engineering Ensuring Stability, Quality & Clonality	Track 2 – Upstream Bioprocessing	Track 3 – Gene Therapy Discovery & Development	Track 4 – Cell & Gene Therapy Analytics & Quality Control	Track 5 – Tissue Engineering Development	Track 6 – Strategies & Challenges For Gene Therapy Manufacturing	Track 7 – Supply Chain, Logistics & Commercialisation	Start Up Zone Programme
16.55 - 17.20	 Panel Discussion: Novel Formats For Cell Line Engineering CRISPR-based multiplexed editing platforms Synthetic chromosome & episomal vector systems Cell free systems Automated microfluidic & Al-driven screening 	Industry Presentation: Scaling Up CONFIRMED: Bart Royens, Senior Process Engineer, Manufacturing Sciences, Sanofi	Industry Presentation: Improving Genetic Expression & Targeted Delivery RESERVED: Henning Stennicke, Chief Scientific Officer, Spur Therapeutics	Industry Presentation: Establishing Comprehensive Analytical Development Program For Autoimmune Diseases • Phase-appropriate and risk-based method development, qualification and validation • Maximizing analytics work to reach first in clinics in the resource constrained biotech environment CONFIRMED: Chien-Chung Chen, Director of Analytical Development, Cabaletta Bio	Industry Presentation: Stem Cells For Diabetes	Industry Presentation: Challenges Associated With Conducting Medical In-Use Stability Studies For CGT IMPs CONFIRMED: Yaser Alkhatib, Head Of Laboratory, Boehringer Ingelheim	 Panel Discussion Sustainability In The CGT Supply Chain Sustainable sourcing & materials management Circular economy potential Supply chain resilience & risk mitigation 	Start-Up Pitch x2
17.20 - 17.45	Panellist: Vincenzo Di Cerbo, Lead Scientist, Cell and Gene Therapy	Industry Presentation: Integrated Continuous Biomanufacturing Processes CONFIRMED: Felix Roth, Senior Scientist,	Industry Presentation: Next-Gen Strategies: Gene Editing Technologies	Industry Presentation: Non-Viral Delivery of CRISPRa Tools for Scalable Directed Differentiation of Induced Pluripotent Stem Cells CONFIRMED: Vincenzo Di Cerbo, Lead Scientist, Cell and	Industry Presentation: Stem Cells For Cartilage	Industry Presentation: Gene Therapy For Rare Disorders CONFIRMED: Jose Bonafont, Principal Scientist,	Panellist: Panos Kefalas, Director of Access Strategy, Cell & Gene Therapy Catapult	Start-Up Pitch x2
17.45	Catapult	AstraZeneca		Gene Therapy Catapult End o	f Day 1	DanausGT		
			Networki	ng Drinks Opened by the E	vent Moderator & Cana	pé Reception		

	Morning Roundtables with	h Continental Breakfast x4								
	Roundtable 1: Market Access Of AMPTs Explore opportunities and challenges for ATMP market access in the UK while also comparing & contrasting with other geographies • Marketing authorization • Health Technology Assessment Frameworks • Commissioning policies • Real world evidence • Considerations on prioritising geographies for launch Moderator: Panos Kefalas, Director of Access Strategy, Cell & Gene Therapy Catapult		Roundtable 2: Future E Manufacturing Small to large scale p Patient's experience Process closure and 	Bullet Proof CAR-T Roundtable 3: Data Integrity processes • Ensuring compliance & accuracy automation • Overcoming challenges in complex woll • Regulatory and technological alignment		& accuracy es in complex workflows ological alignment	Roundtable 4: Patient Engagement			
			Moderator: Sarah Snykers, Senior Director of Operations, Legend Biotech		Co-Moderators: Christopher Middendor Hogan Lovells & Sally G Hogan Lovells	f, Senior Director, u, Senior Associate,				
	Cell Culture & Bioproce	essing	Advanced Therapy Development			Cell & Gene Therapy M	anufacturing			
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 – Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 – Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics In Cell & Gene Therapies Manufacturing	Innovation & Collaboration Programme		
					Part 1 – Cell Therapies					
09.00 - 09.25	Track Keynote Address: Global Cell Bank Management: Generating, Ensuring Quality, and Promoting Sustainability in AstraZeneca	Track Keynote Address: Strategies For Establishing Impurity Clearance & Assessment	Track Keynote Address: Developing Advanced Autologous T Cell Therapies	Track Keynote Address: Clinical Development Of Engineered TCR-T Therapies To Generate A Sarcoma Franchise	Track Keynote Address: Regulatory Landscape for Cell and Gene Therapies: An FDA Perspective	Track Keynote Address: Autologous & Allogenic Products	Track Keynote Address: Smart Manufacturing	Presentation 1: HepatiCan - A Bioartificial Liver To Rescue Patients With Liver Failure CONFIRMED: Clare Selden, Professor of Experimental Hepatology, Iso Presentation 2:		
	CONFIRMED: Gemma Everitt, Senior Research Scientist, UK Cell Culture & Banking, AstraZeneca	CONFIRMED: Julie Beaudet, Chemistry, Manufacturing, & Control Senior Staff Scientist, Regeneron	CONFIRMED: Evangelia Kokalaki, Associate Director of Immunobiology, Autolus	CONFIRMED: Joanna Brewer, Chief Scientific Officer, Adaptimmune	CONFIRMED: Christopher Middendorf, Senior Director, Hogan Lovells	CONFIRMED: Ben Weil, Director For Manufacturing, Royal Free London NHS Foundation Trust	CONFRIMED: Thorsten Gorba, Vice President Process & Analytical Development, Aspen Neuroscience	Title TBC RESERVED: Debesh Mandal, Co- Founder & Chief Executive Officer, Nanograb		

Cell 2025 Day 2 – 12th November 2025

	Cell Culture & Bioproc	essing	Advanced Therapy Dev	velopment		Cell & Gene Therapy M	anufacturing					
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 - Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 – Strategies For Cell Therapy Manufacturing	Track 7 – Automation, AI & Robotics In Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases				
09.25 - 09.50	Industry Presentation: Development Of Human Cell Models To Study The Deregulation Of The Cell Microenvironment	Industry Presentation: AV Gene Therapy Process Development	Industry Presentation: Developing Multispecific Antibodies For Cancer	Industry Presentation: Trial Design & Patient Engagement	Industry Presentation: New Manufacturing Modalities For Cell Therapies And Regulatory Challenges	Industry Presentation: CAR-T EU Manufacturing Footprint: From Start-Up To Commercial Scale Up • Clinical and commercial CAR-T manufacturing • Green- and brown field production CAR-T hubs • Operational readiness and scale up	Industry Presentation: Automation & Digital Strategies For Cell & Gene Therapy Scaling	Presentation 1: Preparing Cell Therapies For Clinics CONFIRMED: Sanjeev Luther, President & Chief Executive Officer, Eterna Therapeutics Presentation 2: Developing CAR-T Therapies For Glioblastoma				
	RESERVED: Catarina Brito, Principal Investigator & Head Of Advanced Cell Models Lab, iBET	CONFIRMED: Parag Kumthekar, Gene Therapy Downstream Process Development Lead, UCB	CONFIRMED: Lydia Caro, Associate Director, Head Of Cell Sciences, Ichnos Sciences	CONFIRMED: Terri Gaskell, Chief Technology Officer, Rinri Therapeutics	CONFIRMED: François Gianelli, Chief Regulatory & Quality Officer, TreeFrog Therapeutics	CONFIRMED: Sarah Snykers, Senior Director of Operations, Legend Biotech	CONFIRMED: Daria Marsh, Head of Bioprocessing, Cell & Gene Therapy Catapult	RESERVED: Evripidis Lanitis, Head of Process Development, Cellula Therapeutics				
09.50 - 10.15	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordg lobal.com	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordg lobal.com	Solution Provider Presentation	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordg lobal.com	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Solution Provider Presentation ThermoFisher	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordg lobal.com	Attendees are welcome to join the co-located presentations				
10.15 - 11.15		lobal.com obal.com lobal.com Morning Coffee & Refreshments Poster Presentation Sessions 1-2-1 Meetings x3										

	Cell Culture & Bioproce	essing	Advanced Therapy Dev	relopment		Cell & Gene Therapy N	lanufacturing	
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 - Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 – Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 - Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics in Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases
11.15 - 11.40	Solution Provider Presentation	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Solution Provider Presentation	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordgl obal.com	Solution Provider Presentation BIOTHRUST	Silver and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxford global.com	Attendees are welcome to join the co-located presentations
11.40 - 12.05	Industry Presentation: Media Optimisation For High Density CONFIRMED: Niraimathi Govindasamy, Senior Scientist. Bluu Bio	Industry Presentation: Development Of Purification Processes RESERVED: Cristina Peixoto, Head Of Downstream Process Development Lab & Coordinator Of Bioproduction Unit, iBET	Industry Presentation: Ongoing CAR-T Development RESERVED: Ermir Kalaj, Chief Executive Officer, Cellula Therapeutics	 Panel Discussion: Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind What is effective and what is not Applications of filing R&D - how this process works in different geographies Patent engagement 	Industry Presentation: Using Accelerated Regulatory Pathways	 Panel Discussion: Developing & Manufacturing Cell Therapies In Large Scale Utilisation of tools - isolators, cell selection technologies Scaling up technologies 	Industry Presentation: Automation In Cell Therapy Manufacturing To Enhance Efficiency And Quality RESERVED: Sarah Kempster, Head Of Serological Standards, SR&I Diagnostics. MHRA	Presentation 1: Title TBC RESERVED: Nozhat Choudry, Vice President Of Clinical Development, Nanoscope Therapeutics Presentation 2: Neonatal Cardiac Progenitor Cells And Their Secretomes RESERVED: Sudhish Sharma, Co- Founder & Director Of Preclinical Studies, Secretome Therapeutics

Cell 2025 Day 2 – 12th November 2025

	Cell Culture & Bioproce	essing	Advanced Therapy Development			Cell & Gene Therapy Manufacturing		
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 - Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 – Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics in Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases
12.05 - 12.30	Industry Presentation: Advances In 3D Cultures And Their Role In Translational Research CONFIRMED: Aline Miller, Professor, University of Manchester	Industry Presentation: Reducing Timelines In Bioprocessing	Industry Presentation: Killer	Panel Discussion Continued: Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind <i>Moderator:</i> Panteli Theocharous, Chief Therapeutics Officer & Head Of Medical & Scientific Affairs, Garuda Therapeutics <i>Panellists:</i> Terri Gaskell, Chief Technology Officer, Rinri Therapeutics Joanna Brewer, Chief Scientific Officer, Adaptimmune Nitin Patel, Vice President Of Late- Stage Clinical Development, Legend Biotech	Industry Presentation: Considerations For Rare Disease & Innovative Clinical Trial Designs	Panel Discussion Continued: Developing & Manufacturing Cell Therapies In Large Scale Scale Moderator: Tiffany Rau, Professor Biochemistry & Cell Biology, University College Cork Panellist: Jose Bonafont, Principal Scientist, DanausGT	Industry Presentation: Industry 4.0 - Benefits Of Al/Automation In Manufacturing CONFIRMED: Himansu Patel, Head of Quality Innovation, Cell and Gene Therapy Catapult	Q&A with the 'Innovation & Collaboration Showcases' Track Speakers
12.30 - 12.55	Solution Provider Presentation	Silver and Above Solution Provider Presentation	Silver and Above Solution Provider Presentation	Silver and Above Solution Provider Presentation	Silver and Above Solution Provider Presentation	Solution Provider Presentation	Silver and Above Solution Provider Presentation	
	CONCEPT LIFE SCIENCES	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	CellforCure	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	Attendees are welcome to join the co-located presentations

	Cell Culture & Bioprocessing		Advanced Therapy Development			Cell & Gene Therapy I				
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 – Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 - Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics in Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases		
12.55 - 13.55	Lunch, Poster Presentation Sessions, 1-2-1 Meetings x3 'Women in Life Sciences' Panel Discussion on the 'Visionary Voices' Stage Breaking barriers & shaping the future Building inclusive working environments Fostering the next generation									
13.55 - 14.20	Panel Discussion: Overcoming The Challenges Of Moving From In Vivo	Industry Presentation: Host Cell Proteins & Removing Impurities	Therapy Development Industry Presentation: Advancing A Pipeline Of Cell Therapies In	Industry Presentation: Phase 3 Trials For A Cell Therapy For	Panel Discussion: Navigating Global Regulatory Challenges In Cell &	Industry Presentation: Platform Concepts – How CAR-Ts Can Be	Panel Discussion: Bridging The Gap Between R&D And Manufacturing For	Panel Discussion: Challenges Of Navigating Development &		
	 In Vitro To 3D Cell Models Modelling approaches Modelling complex organ tissues Qualification & validation 		Regenerative Medicine CONFIRMED: Peter Andersen, Chief Research & Development Officer, TreeFrog Therapeutics	CONFIRMED: Amit Rakhit, Chief Medical Officer, BlueRock Therapeutics	 Gene Therapy Diverging regulatory pathways Exploring ongoing initiatives for global regulatory convergence Lessons learned from the past 10 years of ATMPs in the stage of 	Manufactured & Streamlining The Pipelines	 Digital & Automation Solutions Moving from discovery through the pipeline Challenges in technology implementation Benefits to scalability of 	 How To Get To The Clinic Funding: How to start strategizing to secure funding Regulatory guidelines Manufacturing priorities 		
14.20 - 14.45	Moderator: Rhiannon David, Director, Advanced Cell Models / Microphysiological Systems, AstraZeneca Panellists: Aline Miller, Professor, University of Manchester	Industry Presentation: Downstream Processing Of Cell Culture-Derived Virus Particles	Industry Presentation: iPSC-Derived NK Cells For Immunotherapies RESERVED: Tatyana Ponomaryov, Principal Scientist,	Industry Presentation: Cell Therapy Discovery Case Study RESERVED: Thorsten Gorba, Vice President Process & Analytical Development, Aspen	standardization Moderator: Sally Gu, Senior Associate, Hogan Lovells Panellists: François Gianelli, Chief Regulatory & Quality Officer, TreeFrog Therapeutics Christopher Middendorf, Senior	Industry Presentation: Sustainable Manufacturing	manufacturing Moderator: Tiffany Rau, Professor Biochemistry & Cell Biology, University College Cork Panellists: Daria Marsh, Head of Bioprocessing, Cell & Gene Catapult Lydia Caro, Associate Director, Head Of Cell Sciences, Ichnos	Panellists: Sanjeev Luther, President & Chief Executive Officer, Eterna Therapeutics		

Cell 2025 Day 2 – 12th November 2025

	Cell Culture & Bioprocessing		Advanced Therapy Development			Cell & Gene Therapy Manufacturing			
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 – Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 - Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics in Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases	
14.45 - 15.10	Solution Provider Presentation	Bronze and Above Solution Provider Presentation	Bronze and Above Solution Provider Presentation	Bronze and Above Solution Provider Presentation	Bronze and Above Solution Provider Presentation	Bronze and Above Solution Provider Presentation	Bronze and Above Solution Provider Presentation		
	PHC Europe A Member of PHC Group.	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxford</u> <u>global.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordgl</u> <u>obal.com</u>	Attendees are welcome to join the co-located presentations	
15.10 - 15.35	Industry Presentation: Real-World Examples Of Assay Development And Validation	Industry Presentation: Reducing Timelines In Bioprocessing	Industry Presentation: Cell Therapy For Inflammatory Diseases Via Neonatal Cardiac Progenitor Cells RESERVED: Rachana Mishra, Director Of Cell Biology & Co- Founder, Secretome Therapeutics	Industry Presentation: Late Stage Clinical Development For The Cilta-cel Programme CONFIRMED: Nitin Patel, Vice President Of Late- Stage Clinical Development, Legend Biotech	Industry Presentation: ATMP Commissioning CONFIRMED: Sarah McAleer, Pharmacy Lead – Innovative Treatments, NHS England	Industry Presentation: Streamlining Success Through Bioprocessing Decisions	Industry Presentation: Automated Cell Therapy Manufacturing	Presentation 1 Presentation 2	
15.35 - 15.50	Afternoon Coffee & Refreshments Poster Presentation Sessions								

	Cell Culture & Bioprocessing		Advanced Therapy Development			Cell & Gene Therapy Manufacturing			
	Track 1 – Generation & Validation Of Pre- Clinical Models: Cell Culture Media & 3D Cultures	Track 2 – Downstream Bioprocessing	Track 3 – Cell Therapy Discovery & Development	Track 4 – Clinical Development & Clinical Trials For Cell & Gene Therapies	Track 5 – Regulatory Considerations & Commercialisation For Cell & Gene Therapies	Track 6 - Strategies For Cell Therapy Manufacturing	Track 7 – Automation, Al & Robotics in Cell & Gene Therapies Manufacturing	Innovation & Collaboration Showcases	
15.50 - 16.15 16.15 - 16.40	Industry Presentation: Insights Into Gene Target Validation And Optimisation	Panel Discussion: Streamlining Bioprocessing: Automation & Integration In Downstream Workflows & Post Approval Considerations • Rapid optimisation • Process integration • Future trends • Post approval	Panel Discussion: Assessing Current & Future Opportunities In Bringing Cell Therapies To The Autoimmune Space • Current landscape • Identifying unmet needs & new targets	Industry Presentation: Cell Therapy Discovery Case Study CONFIRMED: Clare Selden, Professor of Experimental Hepatology, University College London Industry	Industry Presentation: Applications Of Biomarkers For Accelerated Regulatory Pathways	Industry Presentation: Ensuring Sustainable Product Pipeline Industry	Industry Presentation: How AI Can Accelerate The Manufacturing Of Cell And Gene Therapies	Presentation 1 Presentation 2 Presentation 1	
	Presentation: Optimizing Cell Culture & Media Development	Panellists: Parag Kumthekar, Gene Therapy Downstream Process Development Lead, UCB	Panellist: Chien-Chung Chen, Director of Analytical Development, Cabaletta Bio	Presentation: Immunohistochemis try	Presentation: Ex Vivo Gene Therapy Approaches	Presentation: Choosing The Right Starting Materials	Presentation: Novel Manufacturing Platforms	Presentation 2	
16.40 - 17.05	Industry Presentation: Techniques For Enhancing Cell Culture Productivity	Industry Presentation: Purification Advancements	Industry Presentation: Strategies To Control And Optimise Stem Cell Bioprocessing	Industry Presentation: Cytokine Profiling	Industry Presentation: Strategies For Rare Diseases	Industry Presentation: Key Challenges With Cell Therapy Manufacturing	Industry Presentation: Computational Tools For Gene-Based Therapy Production	Q&A with the 'Innovation & Collaboration Showcases' Track Speakers	
17.05	End of Congress								